Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAL
NCT01169259Phase 3Active, not recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Jul 2010
- Primary completion
- Nov 2018
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vitamin d and omega-3 fatty acid in cancer and cardiovascular disease (CVD) (4 arms), sponsored by Brigham and Women's Hospital. Primary endpoints: Number of Participants With Invasive Cancer of Any Type at 5 years and Number of Participants With a Major Cardiovascular Event at 5 years. Started Jul 2010; status: active, not recruiting.
02
Drugs
vitamin domega-3 fatty acid
03
Conditions
cancercardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT01169259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01169259.